http://www.sciencedaily.com/news/health_medicine/ovarian_cancer/ Information about ovarian cancer symptoms and treatments. Explore the latest medical research on ovarian cysts and ovarian cancer including including stages of the disease and new treatment options. en-us Fri, 10 Oct 2008 23:05:01 EDT Fri, 10 Oct 2008 23:05:01 EDT 60 http://www.sciencedaily.com/images/logosmall.gif http://www.sciencedaily.com/news/health_medicine/ovarian_cancer/ For more science articles, visit ScienceDaily. http://www.sciencedaily.com/releases/2008/10/081007192441.htm Women who have had early stage breast cancer surgically removed, and whose tumor cells are stimulated by the hormone estrogen, can benefit from taking luteinizing hormone releasing hormone antagonists, a Cochrane systematic review has concluded. This medication may be taken alone or alongside the use of tamoxifen. Fri, 10 Oct 2008 20:00:00 EDT http://www.sciencedaily.com/releases/2008/10/081007192441.htm http://www.sciencedaily.com/releases/2008/10/081007120429.htm Scientists have created a peptide that binds to Bcl-2, a protein that protects cancer cells from programmed cell death, and converts it into a cancer cell killer. The research may lead to new cancer treatments. Fri, 10 Oct 2008 02:00:00 EDT http://www.sciencedaily.com/releases/2008/10/081007120429.htm http://www.sciencedaily.com/releases/2008/09/080923164539.htm Researchers have identified TEM1 as a specific genetic marker for the vascular cells associated with tumor growth, a finding that could aid in diagnosis and treatment of ovarian cancer. Mon, 29 Sep 2008 11:00:00 EDT http://www.sciencedaily.com/releases/2008/09/080923164539.htm http://www.sciencedaily.com/releases/2008/09/080923121952.htm Investigators have achieved a substantial "kill" of pancreatic cancer cells by using nanoparticles to successfully deliver a deadly diphtheria toxin gene. The findings reflect the first time this unique strategy has been tested in pancreatic cancer cells, and the success seen offers promise for future pre-clinical animal studies, and possibly, a new clinical approach. Wed, 24 Sep 2008 20:00:00 EDT http://www.sciencedaily.com/releases/2008/09/080923121952.htm http://www.sciencedaily.com/releases/2008/09/080915083717.htm An investigational drug that combats ovarian cancer by inhibiting the formation of new blood vessels has shown promise in a phase II trial, according to new research. Tue, 16 Sep 2008 02:00:00 EDT http://www.sciencedaily.com/releases/2008/09/080915083717.htm http://www.sciencedaily.com/releases/2008/09/080915083351.htm Women with recurrent ovarian cancer can be helped by an experimental therapy using a drug already touted for its ability to fight other cancers, a finding that provides hope for improved treatment of this deadly disease. Mon, 15 Sep 2008 20:00:00 EDT http://www.sciencedaily.com/releases/2008/09/080915083351.htm http://www.sciencedaily.com/releases/2008/08/080828093351.htm Researchers have found evidence explaining why a common chemotherapy drug, cisplatin, may not always work for every cancer patient. They have shown that when a variant version of a key protein that normally causes cell death is active, patients may be resistant to the cancer-killing drug. Fri, 29 Aug 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/08/080828093351.htm http://www.sciencedaily.com/releases/2008/07/080716101257.htm Scientists have developed a potential new treatment against cancer that attaches magnetic nanoparticles to cancer cells, allowing them to be captured and carried out of the body. The treatment has been tested in the laboratory and will now be looked at in survival studies. Tue, 22 Jul 2008 02:00:00 EDT http://www.sciencedaily.com/releases/2008/07/080716101257.htm http://www.sciencedaily.com/releases/2008/07/080715071412.htm Researchers connect overexpression of tissue type transglutaminase with poor prognosis in ovarian cancer, identify the relevant pathway, and shut TG2 down with an siRNA liposomal nanoparticle. They previously pinpointed TG2's role in resistant and metastatic melanoma and breast and pancreatic cancers. This crucial protein fuels different cancers through different pathways. Thu, 17 Jul 2008 23:00:00 EDT http://www.sciencedaily.com/releases/2008/07/080715071412.htm http://www.sciencedaily.com/releases/2008/07/080707100201.htm Researchers have shown for the first time that it is possible to stimulate a woman's ovaries to produce eggs for collection during the final phase of the menstrual cycle. The finding offers the chance for more women who have been diagnosed with cancer to restore their fertility following chemotherapy or radiotherapy -- cancer treatments that can seriously damage the ovaries, often permanently. Wed, 09 Jul 2008 11:00:00 EDT http://www.sciencedaily.com/releases/2008/07/080707100201.htm http://www.sciencedaily.com/releases/2008/06/080625112310.htm A recently discovered, but not yet understood, section of chromosome 8, called 8q24, may contain at least five distinct regions that are associated with different cancers, according to a study in the June 24 issue of the Journal of the National Cancer Institute. Thu, 26 Jun 2008 20:00:00 EDT http://www.sciencedaily.com/releases/2008/06/080625112310.htm http://www.sciencedaily.com/releases/2008/06/080626090901.htm New research explored whether ovarian cancer has a scent different from other cancers and whether working dogs could be taught to distinguish it in its different stages. Ovarian cancer has a high mortality rate, primarily due to late diagnosis. Researchers found that early-stage and low grade ovarian cancers emit the same scent as advanced tumors. Thu, 26 Jun 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/06/080626090901.htm http://www.sciencedaily.com/releases/2008/06/080623092557.htm Women's reports of persistent, recent-onset symptoms linked to ovarian cancer -- abdominal or pelvic pain, difficulty eating or feeling full quickly and abdominal bloating -- when combined with the CA125 blood test may improve the early detection of ovarian cancer by 20 percent. Tue, 24 Jun 2008 02:00:00 EDT http://www.sciencedaily.com/releases/2008/06/080623092557.htm http://www.sciencedaily.com/releases/2008/06/080616115733.htm Combined positron emission tomography and computed tomography scanning of patients in the early stages of ovarian cancer can enable physicians to determine whether the cancer has spread to nearby lymph nodes without having to perform surgery. As a result, unnecessary surgeries could be reduced, which would also lower morbidity rates and postoperative complications for ovarian cancer patients. Mon, 16 Jun 2008 00:00:00 EDT http://www.sciencedaily.com/releases/2008/06/080616115733.htm http://www.sciencedaily.com/releases/2008/05/080530095450.htm Pre-menopausal breast cancer survivors who were treated with chemotherapy following surgery were more likely to have diminished ovarian reserve -- the capacity of the ovaries to provide eggs capable of being fertilized -- compared to women who have never had breast cancer, according to a study led by Dana-Farber Cancer Institute investigators. Their findings will be presented at the annual meeting of the American Society of Clinical Oncology Mon, 02 Jun 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/05/080530095450.htm http://www.sciencedaily.com/releases/2008/05/080522120601.htm Mutations in a gene called FIGLA cause premature ovarian failure in at least a percentage of women who suffer from the disorder. Thu, 22 May 2008 00:00:00 EDT http://www.sciencedaily.com/releases/2008/05/080522120601.htm http://www.sciencedaily.com/releases/2008/05/080513145249.htm A chemical compound derived from vitamin A prevents cancer from forming and is being developed by the National Cancer Institute as a daily preventive pill. The compound, which still faces several rounds of clinical trials, successfully stopped normal cells from turning into cancer cells and inhibited the ability of tumors to grow and form blood vessels. If successful tests continue, researchers eventually hope to create a daily pill that would be taken as a cancer preventive. Wed, 14 May 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/05/080513145249.htm http://www.sciencedaily.com/releases/2008/05/080508115829.htm Scientists have identified a new gene that causes cancer. The gene and its protein, both called RBM3, are vital for cell division in normal cells. In cancers, low oxygen levels in the tumors cause the amount of this protein to go up dramatically. This causes cancer cells to divide uncontrollably, leading to increased tumor formation. Fri, 09 May 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/05/080508115829.htm http://www.sciencedaily.com/releases/2008/04/080421191421.htm Cancer patients who have been successfully treated for their disease face the prospect of its return if stored ovarian (or testicular) tissue is transplanted back into their bodies without adequate checks, according to researchers at two university hospitals. And few fertility centers have skills and technology needed to check for residual cancer cells. Thu, 01 May 2008 11:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080421191421.htm http://www.sciencedaily.com/releases/2008/04/080423115925.htm It has been reported for the first time in Germany that healthy ovarian tissue has been taken from a nonpregnant woman with cancer and then reimplanted after cancer therapy. The patient is now 32-years-old, and could become pregnant as a result. Thu, 24 Apr 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080423115925.htm http://www.sciencedaily.com/releases/2008/04/080417145744.htm In a discovery that may be useful for maintaining remission in chemo-resistant ovarian cancer, Yale scientists report that pre-clinical studies have shown the drug compound NV-128 can induce the death of ovarian cancer cells by halting the activation of a protein pathway called mTOR. Mon, 21 Apr 2008 11:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080417145744.htm http://www.sciencedaily.com/releases/2008/04/080415194433.htm Recent discoveries about the role of stem cells in cancer have altered the landscape of cancer research. As scientists learn more their cancer-initiating properties, stem cells are emerging as potential therapeutic targets for many types of cancers. Studies presented at the 2008 Annual Meeting of the American Association for Cancer Research, April 12-16, report stem cell discoveries related to pancreatic, bladder, ovarian, and breast cancer and glioma. Mon, 21 Apr 2008 05:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080415194433.htm http://www.sciencedaily.com/releases/2008/04/080417152031.htm Researchers have identified, characterized and cloned ovarian cancer stem cells and have shown that these stem cells may be the source of ovarian cancer's recurrence and its resistance to chemotherapy. Fri, 18 Apr 2008 05:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080417152031.htm http://www.sciencedaily.com/releases/2008/04/080415111702.htm Researchers have shown that the investigational drug triphendiol causes cell death in pancreatic and bile duct cancer cell lines, slows tumor growth and sensitizes tumors to chemotherapy treatments. Scientists assessed the potential of triphendiol as a treatment for pancreatic adenocarcinoma using three representative cell lines. Wed, 16 Apr 2008 17:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080415111702.htm http://www.sciencedaily.com/releases/2008/04/080404183243.htm Like most women with ovarian cancer, 44-year-old Christine Sable of Lancaster, Pennsylvania, did not discover she had the disease until it was in the advanced stages and had spread to other areas of the abdomen. "I knew my chances of recurrence were very high--75 to 80 percent at that particular stage--and that the disease would likely recur within a year or two," she says. "Once it recurs, it is difficult to cure." Mon, 07 Apr 2008 14:00:00 EDT http://www.sciencedaily.com/releases/2008/04/080404183243.htm http://www.sciencedaily.com/releases/2008/03/080313185738.htm A drug that blocks production of an enzyme that enables ovarian cancer to gain a foothold in a new site can slow the spread of the disease and prolong survival in mice, but only if the drug is given early in the disease process. Tue, 18 Mar 2008 08:00:00 EDT http://www.sciencedaily.com/releases/2008/03/080313185738.htm http://www.sciencedaily.com/releases/2008/03/080310155228.htm Recurrent low-grade serous carcinoma, a rare type of ovarian cancer, is less sensitive to chemotherapy and therefore more difficult to treat than more common high-grade ovarian cancers, according to researchers. Thu, 13 Mar 2008 02:00:00 EDT http://www.sciencedaily.com/releases/2008/03/080310155228.htm http://www.sciencedaily.com/releases/2008/03/080311165937.htm Dutch ovarian cancer patients who were treated at a semi-specialized or specialized hospital survived longer than those treated at a general hospital, according to a new study. Tue, 11 Mar 2008 00:00:00 EDT http://www.sciencedaily.com/releases/2008/03/080311165937.htm http://www.sciencedaily.com/releases/2008/02/080227121846.htm Thalidomide, a drug blamed in the 1950s for causing birth defects, is now showing promise as a safe and effective treatment for women with recurrent ovarian cancer, according to a new study. Fri, 29 Feb 2008 11:00:00 EST http://www.sciencedaily.com/releases/2008/02/080227121846.htm http://www.sciencedaily.com/releases/2008/02/080226162848.htm A protein that stimulates blood vessel growth worsens ovarian cancer, but its production can be stifled by a tiny bit of RNA wrapped in a fatty nanoparticle, a research team reports. This research demonstrates that high IL-8 expression in tumors is associated with advanced tumor stage and earlier death for ovarian cancer patients. Thu, 28 Feb 2008 05:00:00 EST http://www.sciencedaily.com/releases/2008/02/080226162848.htm http://www.sciencedaily.com/releases/2008/02/080221093550.htm A new anti-cancer agent that targets breast cancer can overcome resistance to cancer drugs, according to a new study. Many tumours that are initially responsive to chemotherapy can develop resistance to it, allowing the cancer to progress. Studies have shown that one of the key reasons for the development of resistance is a protein pump called P-glycoprotein. Resistant cancer cells express P-glycoprotein and this removes anti-cancer drugs from the cell before they are able to kill the cell. Mon, 25 Feb 2008 08:00:00 EST http://www.sciencedaily.com/releases/2008/02/080221093550.htm http://www.sciencedaily.com/releases/2008/02/080212144500.htm A new blood test has enough sensitivity and specificity to detect early stage ovarian cancer with 99 percent accuracy. The Early Detection Research Network of the National Cancer Institute independently evaluated the results of the test. Wed, 13 Feb 2008 08:00:00 EST http://www.sciencedaily.com/releases/2008/02/080212144500.htm http://www.sciencedaily.com/releases/2008/02/080210145843.htm Scientists have identified a new mechanism that explains why some recurrent ovarian tumors become resistant to treatment with commonly used platinum-based chemotherapy drugs such as cisplatin and carboplatin. The mechanism of cisplatin resistance 'unlike any previously identified.' Mon, 11 Feb 2008 17:00:00 EST http://www.sciencedaily.com/releases/2008/02/080210145843.htm http://www.sciencedaily.com/releases/2008/01/080126194137.htm The contraceptive pill gives women substantial and long-lasting protection against ovarian cancer, according to a new report. The researchers found that the protection against ovarian cancer lasted for more than 30 years after women had stopped taking the Pill. They also found that the longer the Pill was used the greater the protection and that taking the Pill for 15 years halved the risk of ovarian cancer. Sun, 27 Jan 2008 08:00:00 EST http://www.sciencedaily.com/releases/2008/01/080126194137.htm http://www.sciencedaily.com/releases/2008/01/080122101945.htm A new study has found that cigarette smoking and alcohol consumption do not have an effect on ovarian cancer risk, while caffeine intake may lower the risk, particularly in women not using hormones. Tue, 22 Jan 2008 20:00:00 EST http://www.sciencedaily.com/releases/2008/01/080122101945.htm http://www.sciencedaily.com/releases/2008/01/080101184644.htm Israeli investigators have found that Ashkenazi Jewish women with ovarian cancer who have mutations in the BRCA1 or BRCA2 genes lived significantly longer than Ashkenazi Jewish ovarian cancer patients without these mutations. After up to nine years of follow-up, BRCA1/2 mutation carriers were 28 percent less likely to die from the disease, even though women with the BRCA mutations are significantly more likely to develop ovarian and breast cancers. Wed, 02 Jan 2008 14:00:00 EST http://www.sciencedaily.com/releases/2008/01/080101184644.htm http://www.sciencedaily.com/releases/2007/12/071226003841.htm Among breast cancer patients, both chemotherapy and tamoxifen independently reduced the risk of developing a second cancer in the other breast, according to a study published online Dec. 25 in the Journal of the National Cancer Institute. The risk reduction persisted for at least 10 and 5 years, respectively. Thu, 27 Dec 2007 08:00:00 EST http://www.sciencedaily.com/releases/2007/12/071226003841.htm http://www.sciencedaily.com/releases/2007/12/071210163425.htm Scientists have uncovered critical new details about the mechanisms that modulate the response of ovarian cancer cells to chemotherapy. The research, published by Cell Press in the December issue of Cancer Cell, helps to explain why many patients develop resistance to the taxane class of drugs and may lead to improved treatment of ovarian cancer. Wed, 12 Dec 2007 08:00:00 EST http://www.sciencedaily.com/releases/2007/12/071210163425.htm http://www.sciencedaily.com/releases/2007/11/071119184042.htm Frequent consumption of foods containing the flavonoid kaempferol, including nonherbal tea and broccoli, was associated with a reduced risk of ovarian cancer. The researchers also found a decreased risk in women who consumed large amounts of the flavonoid luteolin, which is found in foods such as carrots, peppers, and cabbage. Tue, 20 Nov 2007 11:00:00 EST http://www.sciencedaily.com/releases/2007/11/071119184042.htm http://www.sciencedaily.com/releases/2007/11/071115083704.htm Kisspeptin and its receptor GPR54 predict a favorable clinical outcome in women with ovarian carcinoma, and are specific for the clear cell carcinoma subtype according to a new article. Mon, 19 Nov 2007 11:00:00 EST http://www.sciencedaily.com/releases/2007/11/071115083704.htm http://www.sciencedaily.com/releases/2007/11/071109111607.htm New research explains why some ovarian cancer patients are dying, while others survive, despite similar surgical and post-operative treatment. The findings show that the difference between life and death can many times be explained by the different biological properties of the tumors. Thu, 15 Nov 2007 08:00:00 EST http://www.sciencedaily.com/releases/2007/11/071109111607.htm http://www.sciencedaily.com/releases/2007/11/071113165645.htm Experts examining patterns in ultrasound images can more accurately classify ovarian tumors as benign or malignant than can pre-surgical blood tests, according to a new study. Wed, 14 Nov 2007 08:00:00 EST http://www.sciencedaily.com/releases/2007/11/071113165645.htm http://www.sciencedaily.com/releases/2007/10/071031125501.htm A biologic anticancer agent that prevents tumor growth by interfering with the formation of new blood vessels (Bevacizumab) may have the potential to improve the efficacy of standard combination chemotherapy in ovarian cancer. Thu, 01 Nov 2007 17:00:00 EDT http://www.sciencedaily.com/releases/2007/10/071031125501.htm http://www.sciencedaily.com/releases/2007/10/071030160940.htm The Seneca Valley Virus is a potent cancer killer and can differentiate between normal and cancerous cells. The virus may be a potential treatment for some metastatic cancers, such as small-cell lung cancer. Thu, 01 Nov 2007 05:00:00 EDT http://www.sciencedaily.com/releases/2007/10/071030160940.htm http://www.sciencedaily.com/releases/2007/10/071023163911.htm Mayo Clinic has reported promising interim results from a Phase II trial of a new combination therapy for patients with recurrent ovarian cancer that is resistant to platinum therapy. Women with late-stage ovarian cancer have very few options, and most standard treatments include platinum-based therapies (cell-damaging agents). Wed, 24 Oct 2007 17:00:00 EDT http://www.sciencedaily.com/releases/2007/10/071023163911.htm http://www.sciencedaily.com/releases/2007/10/071004085229.htm The emergence of drug-resistant tumors means chemotherapy no longer holds the promise of a good outcome for many patients. Researchers have now uncovered a new way in which a cell protein protects cancer cells from a wide range of chemotherapeutic drugs, identifying a possible target for improving treatment outcomes for patients. Mon, 08 Oct 2007 20:00:00 EDT http://www.sciencedaily.com/releases/2007/10/071004085229.htm http://www.sciencedaily.com/releases/2007/09/070927143314.htm An experimental drug has shown promise in extending the survival period for women with recurrent ovarian cancer whose treatment options have dwindled. Early testing data showed that pertuzumab added weeks to the lives of Stage 3 ovarian cancer patients whose disease had returned after treatment with existing chemotherapy. Sun, 30 Sep 2007 14:00:00 EDT http://www.sciencedaily.com/releases/2007/09/070927143314.htm http://www.sciencedaily.com/releases/2007/09/070927204041.htm A new study adds fuel to the debate over whether being fat or inactive affects the risk of developing ovarian cancer. Fri, 28 Sep 2007 17:00:00 EDT http://www.sciencedaily.com/releases/2007/09/070927204041.htm